Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adenosine in controlled reperfusion after valvular heart surgery
IRCT20211225053519N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adenosine in Cardiac valve disease (VHD) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Need for inotropic drugs, Need for anti-arrhythmia drugs and 2 more. Started Feb 2022; status: completed.
02
Drugs
adenosine
03
Conditions
Cardiac valve disease (VHD)
Beyond the preview
Go deeper on IRCT20211225053519N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211225053519N1.